Skip to content

Medical emergency? What to do

FDA wants another trial of Lilly diabetic eye drug

3-RXPublished October 2, 20061 min read

Key points

  • Eli Lilly and Co. said Friday that U.S. regulators want an additional three-year clinical trial for its treatment for eye problems brought on by diabetes.
  • The Food and Drug Administration is calling for additional efficacy data before it will consider approving the molecule for the treatment of moderate to severe diabetic retinopathy.
  • Some analysts had predicted the drug, which had the proposed trade name Arxxant, could have sales of $500 million a year.
  • Lilly said ongoing clinical trials for ruboxistaurin will continue while Lilly evaluates options for its further development.

Eli Lilly and Co. said Friday that U.S. regulators want an additional three-year clinical trial for its treatment for eye problems brought on by diabetes.

Lilly said such a trial would take up to five years to complete. It said it is weighing options for the further development of the treatment, called ruboxistaurin mesylate.

The Food and Drug Administration is calling for additional efficacy data before it will consider approving the molecule for the treatment of moderate to severe diabetic retinopathy.

Last month, Lilly said it received a so-called "approvable letter" from the FDA, rather than approving the drug outright.

Some analysts had predicted the drug, which had the proposed trade name Arxxant, could have sales of $500 million a year.

"We still believe that ruboxistaurin has potential as a treatment for diabetic eye disease and are exploring the feasibility of further development of this molecule," said Dr. John Lechleiter, Lilly president and chief operating officer, in a statement.

Lilly said ongoing clinical trials for ruboxistaurin will continue while Lilly evaluates options for its further development.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.